Cargando…

Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters

Albizia julibrissin Durazz is one of the most common herbs used for depression and anxiety treatment, but its mechanism of action as an antidepressant or anxiolytic drug have not been fully understood. We previously isolated and identified one lignan glycoside compound from Albizia Julibrissin Duraz...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hanhe, Wu, Yingyao, Li, Chan, Tang, Qingfa, Zhang, Yuan-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649612/
https://www.ncbi.nlm.nih.gov/pubmed/36386236
http://dx.doi.org/10.3389/fphar.2022.1018473
_version_ 1784827834364067840
author Liu, Hanhe
Wu, Yingyao
Li, Chan
Tang, Qingfa
Zhang, Yuan-Wei
author_facet Liu, Hanhe
Wu, Yingyao
Li, Chan
Tang, Qingfa
Zhang, Yuan-Wei
author_sort Liu, Hanhe
collection PubMed
description Albizia julibrissin Durazz is one of the most common herbs used for depression and anxiety treatment, but its mechanism of action as an antidepressant or anxiolytic drug have not been fully understood. We previously isolated and identified one lignan glycoside compound from Albizia Julibrissin Durazz, (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside (SAG), that inhibited all three monoamine transporters with a mechanism of action different from that of the conventional antidepressants. In this study, we generated homology models for human dopamine transporter and human norepinephrine transporter, based on the X-ray structure of Drosophila dopamine transporter, and conducted the molecular docking of SAG to all three human monoamine transporters. Our computational results indicated that SAG binds to an allosteric site (S2) that has been demonstrated to be formed by an aromatic pocket positioned in the scaffold domain in the extracellular vestibule connected to the central site (S1) in these monoamine transporters. In addition, we demonstrated that SAG stabilizes a conformation of serotonin transporter with both the extracellular and cytoplasmic pathways closed. Furthermore, we performed mutagenesis of the residues in both the allosteric and orthosteric sites to biochemically validate SAG binding in all three monoamine transporters. Our results are consistent with the molecular docking calculation and support the association of SAG with the allosteric site. We expect that this herbal molecule could become a lead compound for the development of new therapeutic agents with a novel mechanism of action.
format Online
Article
Text
id pubmed-9649612
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96496122022-11-15 Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters Liu, Hanhe Wu, Yingyao Li, Chan Tang, Qingfa Zhang, Yuan-Wei Front Pharmacol Pharmacology Albizia julibrissin Durazz is one of the most common herbs used for depression and anxiety treatment, but its mechanism of action as an antidepressant or anxiolytic drug have not been fully understood. We previously isolated and identified one lignan glycoside compound from Albizia Julibrissin Durazz, (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside (SAG), that inhibited all three monoamine transporters with a mechanism of action different from that of the conventional antidepressants. In this study, we generated homology models for human dopamine transporter and human norepinephrine transporter, based on the X-ray structure of Drosophila dopamine transporter, and conducted the molecular docking of SAG to all three human monoamine transporters. Our computational results indicated that SAG binds to an allosteric site (S2) that has been demonstrated to be formed by an aromatic pocket positioned in the scaffold domain in the extracellular vestibule connected to the central site (S1) in these monoamine transporters. In addition, we demonstrated that SAG stabilizes a conformation of serotonin transporter with both the extracellular and cytoplasmic pathways closed. Furthermore, we performed mutagenesis of the residues in both the allosteric and orthosteric sites to biochemically validate SAG binding in all three monoamine transporters. Our results are consistent with the molecular docking calculation and support the association of SAG with the allosteric site. We expect that this herbal molecule could become a lead compound for the development of new therapeutic agents with a novel mechanism of action. Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9649612/ /pubmed/36386236 http://dx.doi.org/10.3389/fphar.2022.1018473 Text en Copyright © 2022 Liu, Wu, Li, Tang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Hanhe
Wu, Yingyao
Li, Chan
Tang, Qingfa
Zhang, Yuan-Wei
Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters
title Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters
title_full Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters
title_fullStr Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters
title_full_unstemmed Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters
title_short Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters
title_sort molecular docking and biochemical validation of (-)-syringaresinol-4-o-β-d-apiofuranosyl-(1→2)-β-d-glucopyranoside binding to an allosteric site in monoamine transporters
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649612/
https://www.ncbi.nlm.nih.gov/pubmed/36386236
http://dx.doi.org/10.3389/fphar.2022.1018473
work_keys_str_mv AT liuhanhe moleculardockingandbiochemicalvalidationofsyringaresinol4obdapiofuranosyl12bdglucopyranosidebindingtoanallostericsiteinmonoaminetransporters
AT wuyingyao moleculardockingandbiochemicalvalidationofsyringaresinol4obdapiofuranosyl12bdglucopyranosidebindingtoanallostericsiteinmonoaminetransporters
AT lichan moleculardockingandbiochemicalvalidationofsyringaresinol4obdapiofuranosyl12bdglucopyranosidebindingtoanallostericsiteinmonoaminetransporters
AT tangqingfa moleculardockingandbiochemicalvalidationofsyringaresinol4obdapiofuranosyl12bdglucopyranosidebindingtoanallostericsiteinmonoaminetransporters
AT zhangyuanwei moleculardockingandbiochemicalvalidationofsyringaresinol4obdapiofuranosyl12bdglucopyranosidebindingtoanallostericsiteinmonoaminetransporters